Abbvie Supports Two Major Scientific Gatherings In Cairo
Cairo hosted two leading scientific gatherings that brought together distinguished experts and consultants from Egypt and the region, alongside international speakers: the 7th edition of the Middle East, Africa, and Russia (MEAR) Hematology Summit, and the 2nd edition of the ELEVATE Conference on integrated ovarian cancer care. Both events were held with the participation of AbbVie, the global research and development company in the field of biopharmaceuticals.
Held under the auspices of the Egyptian Society of Hematology and Bone Marrow Transplantation and AbbVie, the summit brought together speakers, experts, and consultants specializing in hematology and hematologic malignancies. The sessions addressed the latest developments in the treatment of lymphomas, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, and discussed the role of emerging therapies in reshaping treatment decisions away from traditional chemo-immunotherapy approaches. Interactive workshops also reviewed recent clinical evidence and advanced treatment options.
The second edition of ELEVATE was held under the auspices of the Egyptian Cancer Society. The conference brought together leading oncology experts and consultants from Egypt, Saudi Arabia, the UAE, Russia, and other countries to exchange expertise on the latest approaches to ovarian cancer diagnosis and treatment. Discussions focused on advancing integrated care, improving diagnostics and therapeutic outcomes, and preserving patients' physical, psychological and social well-being. The scientific agenda addressed precision medicine, tumor resistance, interdisciplinary collaboration, digital technologies and the use of artificial intelligence in clinical practice.
The conference concluded with an in-depth discussion of artificial intelligence use cases across the ovarian cancer care pathway, from diagnosis through treatment. The session examined how digital technologies and AI may support physicians by helping analyze medical data and inform treatment decisions. Speakers emphasized that these technologies are intended to complement-not replace-clinical expertise and medical judgment.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment